Fig. 2

Intraperitoneal injection of O-1602 reverses acute restrain stress-induced anxiety-like behavior. a In the EPM, administration of O-1602 increased the time spent in the open arms compared to the vehicle group. O-1602 had no effect on the number of entries in the open arms. Treatment with CID16020046 and O-1602 decreased the time spent in the open arms and had no significant effect on the entries in the open arms compared to the O-1602 group. **p < 0.01 versus control group; ^## p < 0.01 versus vehicle group; ^&& p < 0.01 versus O-1602 group. b In the OFT, O-1602 treatment increased the time spent in the central area slightly and the total distance traveled significantly compared to the vehicle group. CID16020046 and O-1602 treatmentdecreased the total time spent in the central area and the total distance traveled as compared to the O-1602 group. *p < 0.05, **p < 0.01 versus control group; ^# p < 0.05, ^## p < 0.01 versus vehicle group; ^& p < 0.05, ^&& p < 0.01 versus O-1602 group. c Intraperitoneal injection of O-1602 reversed stress-induced expression of GluA1 and GluN2A, while GluN2B were unchanged. CID16020046 and O-1602 treatment abolished O-1602-mediated decrease in GluA1 and GluN2A expression. The expression of GluN2B were unchanged. **p < 0.01 versus control group; ^## p < 0.01 versus vehicle group; ^& p < 0.05, ^&& p < 0.01 versus O-1602 group. Each group contains 6–8 mice. Data are from three independent experiments